Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo

The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS)

(2010) N. Fortunati et al.   BREAST CANCER RESEARCH AND TREATMENT

Histone deacetylase inhibitors that target tubulin

(2009) Jörg Schemies et al.   CANCER LETTERS

Induction of Thyroid Gene Expression and Radioiodine Uptake in Thyroid Cancer Cells by Targeting Major Signaling Pathways

(2009) Peng Hou et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells

(2008) A. Scuto et al.   BLOOD

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

(2008) L. Ellis et al.   CLINICAL CANCER RESEARCH

Histone deacetylase inhibitors in cancer therapy

(2008) Min-Jung Lee et al.   CURRENT OPINION IN ONCOLOGY

Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification

(2008) Rebecca E. Schweppe et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma

(2008) Jennifer A. Woyach et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors

(2008) Martin Haefner et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor κB

(2007) Chie Nishioka et al.   LEUKEMIA RESEARCH